Tirzepatide · Weight management & OSA

Zepbound titrated against your BMI, your comorbidities, and your sleep-apnea picture.

Clara reads your weight trajectory, your weight-related comorbidities (including obstructive sleep apnea), your medication list, and your tolerance history before drafting a starting dose. A physician signs off on every Rx.

Get started How it works

Weight management · 24 weeks on Zepbound

Needs review

Weight (current)222 lb −24 lb from baseline

BMI31.8 obesity class I

Current doseZepbound 7.5 mg weekly unchanged 8 weeks

STOP-BANG (OSA risk)5/8 high risk

Clara: You've lost 10% of body weight on Zepbound 7.5 mg, with tolerable side effects. Your STOP-BANG score still flags high OSA risk. I'll draft a step up to 10 mg and a home sleep apnea test request for our physician to review.

Values and scenarios shown are illustrative examples only. All clinical assessments are individualized and reviewed by a licensed physician.

How it works

Connect your records. Clara reads the full picture. A physician signs off on every clinical action.

Connect your records

Clara auto-syncs your medical records from 150,000+ doctors' offices, hospitals, labs, and pharmacies: every prior lab, every prescription, every diagnosis. Wearable data syncs automatically on Standard and Concierge plans. Free to start, no credit card.

Clara checks candidacy, interactions, and dose

Before drafting any prescription, Clara reads your full chart: indication, contraindications, every drug and supplement on your list, and any prior trials of this medication. The interaction check runs against the full FDA label — not just the common flagged pairs.

Physician-reviewed Rx, then on-clock monitoring

Every prescription is reviewed and signed off by a licensed physician before it reaches your pharmacy. Clara then tracks the key monitoring labs on schedule — not at your next annual visit — and flags when dose adjustment or follow-up is warranted.

About tirzepatide

Tirzepatide: what it treats, who it's for, and what Clara reads before prescribing.

FDA-approved indications

✓Chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbid condition, as an adjunct to a reduced-calorie diet and increased physical activity

✓Moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, as an adjunct to a reduced-calorie diet and increased physical activity

Who Clara evaluates for tirzepatide

✓Adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, OSA, cardiovascular disease)

✓Adults with obesity and confirmed moderate-to-severe obstructive sleep apnea, especially patients who decline or cannot tolerate CPAP

✓Patients already on a stable Zepbound regimen who need dose review, refills, and on-schedule tolerance monitoring

✗Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2

What Clara checks

Four things Clara reads before drafting — and keeps reading after.

🎯

Indication and candidacy

Clara reads your BMI history, your weight-related comorbidities, your STOP-BANG or prior sleep-study results, and your prior weight-management interventions before confirming Zepbound candidacy. It cross-checks your personal and family history for medullary thyroid carcinoma or MEN 2 syndrome — both contraindications — before drafting.

⚠️

Drug and supplement interactions

Zepbound delays gastric emptying and can alter absorption of co-administered oral medications. Tirzepatide may reduce the efficacy of oral contraceptives at therapy initiation and after dose escalation; the label recommends a non-oral backup contraceptive method for 4 weeks after initiation and after each dose increase. Co-administration with insulin or sulfonylureas in patients with concurrent T2D increases hypoglycemia risk.

⚖️

Dose sizing

Per the Zepbound prescribing information, the starting dose is 2.5 mg subcutaneously once weekly for 4 weeks (for tolerance, not weight effect), then 5 mg weekly. Dose may be increased in 2.5 mg increments after at least 4 weeks at the current dose, up to a maximum of 15 mg weekly.¹

📅

On-schedule monitoring

Clara prompts weight and BP rechecks at 1 month and 3 months after initiation, then every 3 months. For OSA indication, Clara reviews symptom response, snoring report, and (where available) home sleep apnea test or polysomnography data alongside the weight trajectory. Renal function is monitored during dose escalation.

Important safety information

Tirzepatide (Zepbound) is a prescription medication. The following is a summary of key safety information from the FDA-approved prescribing information. This is not a complete list — see the full prescribing information linked in the footer.

Boxed warning

In rodent studies, tirzepatide caused thyroid C-cell tumors. It is unknown whether Zepbound causes such tumors in humans. Zepbound is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Warnings

Acute pancreatitis (discontinue if suspected). Acute kidney injury (especially with dehydration from GI side effects). Hypoglycemia when used with insulin or sulfonylureas in patients with T2D. Acute gallbladder disease. Suicidal behavior and ideation. Reduced oral contraceptive efficacy at initiation and dose escalation. The most common adverse reactions are nausea, diarrhea, vomiting, constipation, abdominal pain, fatigue, and injection-site reactions.

Monitoring requirements

Weight, BMI, and BP at baseline and scheduled intervals. Renal function during dose escalation and with volume-depletion symptoms. For OSA indication, periodic re-evaluation of sleep symptoms and home sleep test or polysomnography results where indicated. Mental-health check-ins for emergence of mood changes or suicidal ideation.

Special populations

Pregnancy: discontinue Zepbound when pregnancy is recognized; tirzepatide may cause fetal harm based on animal data. Lactation: limited data; consider risks and benefits. Pediatric: safety and effectiveness not established. Geriatric: no overall dose adjustment, increased monitoring is reasonable. Renal/hepatic impairment: no dose adjustment recommended.

Why Clara

How Clara manages Zepbound differently.

	Clara	Cash-pay DTC weight-loss telehealth	General telehealth	Your doctor
Cost to start	Free (records + chat)	Subscription required	Per-visit fee	$150+ copay
Monthly cost	From $25/mo · Standard $50/mo · HSA/FSA eligible	$199–$299/mo bundled cash-pay	Per-visit, varies	Per-visit copay
Reads full chart before prescribing	✓ Auto-synced, 150,000+ sources	Intake questionnaire only	Self-uploaded only	Within a single practice
Prescribes FDA-approved branded medication (not compounded)	✓ Branded Zepbound	Often compounded tirzepatide	Varies	✓
Prescription may be covered by your insurance	✓	Cash-pay bundled	Varies	✓
Manages weight and OSA together	✓ STOP-BANG, sleep-study review	Weight only	Weight only	Often siloed
Biomarker panel included	✓ 74–108 tests in membership	Extra cost	Extra cost	Per-test copay
Full primary care (beyond weight)	✓	Single-vertical	Single-condition	✓

The AI difference

What an AI that reads your full chart makes possible in primary care.

A clinician in a 15-minute visit reads the last panel. Clara reads every result you've ever had drawn — every lab, every wearable reading, every medication change — and cross-references them in a single pass. That's not a time-management difference. It's a category-of-work difference. The AI handles the data; licensed physicians handle every clinical decision.

Reads your entire chart, every time

Clara auto-syncs from 150,000+ medical sources and reads every prior result, medication, and diagnosis together — not just the last visit's notes. Pattern-finding across years of data is what the AI is built for.

Continuous monitoring, not annual snapshots

Clara watches for drift between visits — a creeping lab value, a wearable trend, a new medication interaction — and surfaces it when it's actionable, not when you happen to schedule an appointment.

Physician review on every clinical action

Clara drafts; physicians decide. Every prescription and lab order is reviewed and signed by a licensed clinician before it reaches your pharmacy or lab. The AI handles intake, reasoning, and follow-up. The physician handles sign-off.

Common questions

Tirzepatide with Clara: questions patients ask.

What does Clara cost?

Connecting your medical records and chatting with Clara is free. To access physician-reviewed prescriptions and lab orders, plans start at $50/month. Standard ($50/mo) includes 74 biomarker tests, wearable integration, and weekly record sync. Concierge ($150/mo) includes 108 biomarker tests and expanded panels. All plans are HSA/FSA eligible. Biomarker panels are included in the membership — not billed separately and not billed to insurance. Medications and ad-hoc lab orders are billed by your pharmacy or lab and may be covered by your insurance.

Can I use my insurance, HSA, or FSA?

Clara's membership is cash-pay and not billed through insurance, but every plan is HSA/FSA eligible. Prescriptions Clara's physicians write go to your pharmacy and may be covered by your plan like any other script — Clara prescribes FDA-approved branded and generic medications, not compounded formulations. Ad-hoc lab orders may also be covered by your insurance when applicable.

Is Clara a real medical practice?

Yes. Clara operates through affiliated professional corporations licensed in all 50 states. All diagnoses, prescriptions, and lab orders are reviewed and signed off by licensed physicians. Clara's AI handles intake, continuous monitoring, and clinical reasoning — the physician sign-off happens before any clinical action reaches you.

How is this different from my regular doctor?

A 15-minute annual visit can review your most recent results. Clara reads every lab you've had drawn, every medication you've been on, and every wearable data point in a single pass — and does it every time you interact, not just at annual visits. Your PCP remains the right choice for in-person exams, procedures, and anything Clara refers out. Clara fills the continuous monitoring gap between visits.

Is my data private?

Clara is HIPAA compliant. Your medical records and wearable data are used solely to personalize your care. They are not sold to third parties and are not used to train public AI models.

What's the difference between Zepbound and Mounjaro?

Both are tirzepatide, the same molecule, made by Eli Lilly. Zepbound is FDA-approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity; Mounjaro is FDA-approved for type 2 diabetes. Different indications, different insurance coverage rules. Clara reviews your diagnoses and prescribes the on-label brand for your situation.

Does Zepbound replace CPAP for sleep apnea?

Not necessarily. Zepbound is FDA-approved as an adjunct to a reduced-calorie diet and increased physical activity for moderate-to-severe OSA in adults with obesity — it does not replace CPAP for patients already on effective CPAP therapy. For some patients with obesity-driven OSA, Zepbound-induced weight loss can meaningfully reduce or eliminate OSA severity, but this is an individualized decision with sleep-study confirmation. Clara reviews your sleep symptoms, CPAP tolerance, and OSA severity before and during treatment.

Does Clara prescribe branded Zepbound or compounded tirzepatide?

Clara's physicians prescribe FDA-approved branded Zepbound, not compounded tirzepatide. Branded Zepbound goes through the standard pharmacy fill and may be covered by your insurance. Compounded tirzepatide is a cash-pay product sold by some telehealth brands; Clara does not use it because the FDA has issued safety concerns about compounded GLP-1 formulations.